CCNA2: Cyclin A2 – Cell Cycle Regulator and Oncogene
Comprehensive genomic and proteomic overview of CCNA2, a key cyclin controlling G1/S and G2/M transitions.
Gene Information Card
| Symbol | CCNA2 |
|---|---|
| Full Name | Cyclin A2 |
| Gene Type | Protein-coding |
| Chromosomal Location | 4q27 |
| NCBI Gene ID | 890 ncbi.nlm.nih.gov/gene/890 |
| Ensembl ID | ENSG00000145386 |
| UniProt ID | P20248 |
| OMIM ID | 123835 |
| HGNC ID | 1578 |
| Aliases | CCN1, CCNA, cyclin-A2 |
Description
CCNA2 (Cyclin A2) is a protein-coding gene that encodes a member of the cyclin family, specifically cyclin A2. This protein is essential for cell cycle control, binding and activating cyclin-dependent kinase 2 (CDK2) and CDK1 to drive progression through the G1/S and G2/M transitions. CCNA2 is frequently overexpressed in various cancers and is associated with poor prognosis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Overexpression of CCNA2 promotes cell proliferation and tumor growth. | PMID: 25691885; COSMIC |
| Colorectal cancer | CCNA2 amplification and high expression correlate with advanced stage and metastasis. | PMID: 27381357; COSMIC |
| Hepatocellular carcinoma | CCNA2 upregulation drives cell cycle progression and is linked to poor survival. | PMID: 29980614; COSMIC |
| Lung cancer | CCNA2 overexpression enhances CDK2 activity, accelerating G1/S transition. | PMID: 31065109; COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 48.2 | High |
| Bone marrow | 35.1 | High |
| Lymph node | 28.7 | High |
| Colon | 12.4 | Medium |
| Lung | 8.9 | Medium |
| Liver | 5.3 | Low |
| Brain | 1.2 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 62.5 | Cervical cancer cell line; high proliferation |
| MCF7 | 45.8 | Breast cancer cell line; estrogen receptor positive |
| A549 | 38.2 | Lung adenocarcinoma cell line |
| HepG2 | 29.1 | Hepatocellular carcinoma cell line |
| K562 | 55.3 | Chronic myeloid leukemia cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.123C>T (p.Arg41Trp) | Missense | <0.1% | Unknown; rare variant |
| c.456G>A (p.Glu152Lys) | Missense | <0.1% | Unknown; rare variant |
| Amplification | Copy number gain | 5-10% in breast cancer | Increased CCNA2 expression and CDK2 activity |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in CCNA2; essential gene for cell cycle.
Gain of Function (GOF)
Amplification and overexpression are common gain-of-function events in multiple cancers.
Dominant Negative (DN)
No dominant-negative mutations described for CCNA2.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Cell Cycle (KEGG hsa04110)
• G1/S Transition (Reactome R-HSA-69206)
• G2/M Transition (Reactome R-HSA-69275)
• CDK-mediated phosphorylation and removal of Cdc6 (Reactome R-HSA-69017)
Protein Summary
Cyclin A2 is a 432-amino acid protein (UniProt P20248) that contains a cyclin box domain. It binds and activates CDK2 and CDK1, regulating both G1/S and G2/M cell cycle transitions. The protein is predominantly nuclear and its expression peaks during S and G2 phases. CCNA2 is a well-established oncogene, with overexpression driving uncontrolled proliferation in many tumor types.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CCNA2 Knockout HAP1 Cell Line | EDJ-KQ78113 | Human | 890 | Details Get a Quote |
| CCNA2 Knockout HEK293T Cell Line | EDJ-KQ78149 | Human | 890 | Details Get a Quote |
Displaying Records 1 To 2 Of 2 Records
